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Simultaneous Detection of EGFR 
and VEGF in Colorectal Cancer using 
Fluorescence-Raman Endoscopy
Yong-il Kim1,2,3, Sinyoung Jeong4,5, Kyung Oh Jung1,6, Myung Geun Song1,6, Chul-Hee Lee1,6, 
Seock-jin Chung1,6, Ji Yong Park1, Myeong Geun Cha4, Sung Gun Lee4, Bong-Hyun Jun7, Yun-
Sang Lee  1,2, Do Won Hwang1,2, Hyewon Youn1, Keon Wook Kang  1, Yoon-Sik Lee8, Dae 
Hong Jeong4 & Dong Soo Lee1,2
Fluorescence endomicroscopy provides quick access to molecular targets, while Raman spectroscopy 
allows the detection of multiple molecular targets. Using a simultaneous fluorescence-Raman 
endoscopic system (FRES), we herein demonstrate its potential in cancer diagnosis in an orthotopically 
induced colorectal cancer (CRC) xenograft model. In the model, epidermal growth factor receptor 
(EGFR) and vascular endothelial growth factor (VEGF) were targeted with antibody-conjugated 
fluorescence and surface-enhanced Raman scattering (F-SERS) dots. FRES demonstrated fast signal 
detection and multiplex targeting ability using fluorescence and Raman signals to detect the F-SERS 
dots. In addition, FRES showed a multiplex targeting ability even on a subcentimeter-sized CRC after 
spraying with a dose of 50 µg F-SERS dots. In conclusion, molecular characteristics of tumor cells (EGFR 
in cancer cell membranes) and tumor microenvironments (VEGF in the extracellular matrix) could be 
simultaneously investigated when performing a colonoscopy.
Colonoscopy (standard white light endoscopy) is an essential tool for the localization and excision of suspected 
neoplastic lesions of colorectal cancer (CRC)1, 2. However, colonoscopy may result in misdiagnosis in up to 25% 
of cases, and polyps without malignant potential might be treated at high risk and cost to the patient3. Recent 
technological advancements in endoscopy procedures have improved the accuracy of endoscopic diagnosis of 
cancer4; examples include chromoendoscopy, light-scattering spectroscopy, autofluorescence imaging, endocys-
toscopy, high-resolution and magnifying endoscopy, etc5.
If applied to endoscopy, molecular imaging provides an opportunity to detect specific molecular targets of 
CRC early6. Fluorescence-based endomicroscopy (FBE) has been utilized to recognize these molecular targets 
in preclinical studies and is now used in clinical practice as a tool in image-guided cancer surgery7. FBE pro-
vides microscopic images using fluorescent dyes at the subcellular level although its use is limited to only one 
fluorescent dye at a time, which has limited the identification of potential multiple targets of a cancer8. Another 
technique, Raman spectroscopy, has also been introduced to discover the molecular characteristics of a cancer 
by distinguishing the inherent vibrational fingerprints of the cancer cells9, 10. Multiplex molecular imaging has 
been performed by utilizing the nanotags of surface-enhanced Raman scattering (SERS) with high sensitivity11–14, 
while its clinical applicability is under evaluation5, 15.
Previously, we adopted duplex fluorescence-SERS (F-SERS) probes against epidermal growth factor receptor 
(EGFR) and human epidermal growth factor receptor-2 (HER2) of breast cancer and combined FBE and Raman 
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spectroscopy as one detection system called FRES (fluorescence-Raman endoscopic system), which successfully 
illustrated its value in subcutaneous tumor implants as a proof-of-concept16.
In orthotopic cancer implants, tumor cells are surrounded by various cells such as fibroblasts, immune and 
blood vessel cells, and also extracellular matrices. These are collectively called the tumor microenvironment in 
which its constitution is associated with the extent of tumor cell proliferation, angiogenesis, invasion, and patients’ 
survival; thus, each constituent should be examined and its role understood17. Hence, in this investigation, as a 
first step to simultaneously imaging a tumor and its microenvironment, we chose two targets for CRC: EGFR and 
vascular endothelial growth factor (VEGF)18. EGFR is targeted by cetuximab and VEGF by bevacizumab, both 
of which are used in clinical practice. Hence, when positive, the successful imaging of these two markers might 
guide their use to target the CRC of interest19.
In this investigation, we aimed to make FRES with F-SERS dots feasible in an orthotopic xenograft model of 
CRC (Fig. 1). Further to the validation of FRES/F-SERS endoscopy of EGFR/HER2, and once again in CRC, we 
validated the duplex targeting capability, the system’s detection limit (sensitivity) and reproducibility, and also 
its capacity for quantification and real-time imaging using F-SERS dots for EGFR (the target of cetuximab) and 
VEGF (the target of bevacizumab).
Results
Design of F-SERS dots and FRES. F-SERS dots consist of silica spheres (ca. 180 nm) as a core, Raman 
active chemical-labeled silver nanoparticles (ca. 10 nm) generating SERS signals, and a fluorescent dye-con-
jugated silica shell emitting fluorescent signals, as shown in Supplementary Fig. 1. Thus, the F-SERS dots are 
able to simultaneously emit SERS and fluorescence signals from a single nanoparticle. Photostability was sus-
tained at more than 90% fluorescence and more than 80% SERS signal for 300 sec continuous laser exposure 
(Supplementary Fig. 2). For multiplex detection, the F-SERS dots were labeled with a single fluorescent dye 
(AF610) and two Raman active molecules: rhodamine B isothiocyanate (RITC) and fluorescein isothiocyanate 
(FITC) for F-SERS-A and -B dots, respectively. F-SERS-A and F-SERS-B dots were conjugated with anti-EGFR 
and anti-VEGF antibodies, respectively, and their mean diameters were 352.5  ± 37.1 nm and 363.8  ± 34.3  nm, 
respectively (Fig. 2a and Supplementary Table 1). Fluorescence signals were represented as small bright dots, and 
Raman signals revealed the highest Raman band at 1648 cm−1 for RITC (EGFR-F-SERS-A dots) and at 1324 cm−1 
for FITC (VEGF-F-SERS-B dots) (Fig. 2b). The limits for detection of fluorescence and SERS signals of F-SERS 
dots were ca. 0.5 pM and ca. 1 pM, respectively16.
Figure 1. Schematic illustration of the in vivo multiplex molecular diagnosis on colorectal cancer using 
simultaneous fluorescence-Raman endoscopic system (FRES). FRES was able to detect fluorescence and Raman 
signals simultaneously for the molecular characterization of a tumor. When antibody-conjugated F-SERS dots 
were sprayed onto HT29-effluc colon cancer cells, the antibody-conjugated F-SERS dots bound to colon cancer 
cells [epidermal growth factor receptor (EGFR)] and tumor microenvironments [vascular endothelial growth 
factor (VEGF)]. FRES simultaneously utilizes the fluorescence signal of a fluorescent silica shell for fast signal 
detection [Alexa Fluor (AF) 610], and the Raman signals for multiplex targeting from the silver nanoparticles 
labeled by two kinds of Raman active compounds [rhodamine B isothiocyanate (RITC, -A) and fluorescein 
isothiocyanate (FITC, -B)].
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Characterization of the colon cancer cell line and FRES results in vitro. HT29-effluc colon can-
cer cells demonstrated gradually increased luciferase activity with seeded cell number and a significant positive 
correlation with protein concentration (R2 = 0.987, P < 0.001). Western blot analysis revealed EGFR and VEGF 
expression in this cancer cell line (Fig. 2c).
Antibody-conjugated F-SERS dots (EGFR-F-SERS-A and VEGF-F-SERS-B) were sprayed onto cultured 
HT29-effluc cells and binding was evaluated using confocal laser scanning microscopy (CLSM). When 10 µg of 
antibody-conjugated F-SERS dots were sprayed, fluorescence signals from them were observed. However, when 
10 µg of IgG-F-SERS dots A/B were sprayed (control), fluorescence was not detected (Fig. 2d).
The in vitro FRES study demonstrated that both fluorescence and Raman signals were detectable from 5 μg 
(104 cells/cm2), and saturation of Raman intensity was observed at 40 μg (104 cells/cm2); the FRES signal became 
distinct as the seeded cell density increased (Fig. 3 and Supplementary Fig. 3).
Orthotopic CRC xenograft modeling after injection of 1 × 107 HT29-effluc cells. HT29-effluc 
orthotopic CRC xenograft model was established in BALB/c nude mice. From a total of 20 mice, 100% (20/20) 
survived one week after injection of 1 × 107 HT29-effluc cells and 70% (14/20) survived after two weeks. Anal 
Figure 2. Characterization of fluorescence and surface enhanced Raman scattering nanoprobes (F-SERS 
dots), FRES, and colon cancer cell lines. (a) The size of the F-SERS and antibody-conjugated F-SERS dots. The 
size of the F-SERS-A and EGFR-F-SERS-A dots was 318.6  ± 20.1 nm and 352.5  ± 37.1 nm, respectively, and 
the size of the F-SERS-B and VEGF-F-SERS-B dots were 326.3  ± 25.9  nm and 363.8  ± 34.3  nm, respectively. 
(b) Evaluation of FRES using antibody-conjugated F-SERS dots. EGFR-F-SERS-A dots showed a small dotted 
fluorescence signal (AF 610) and a 1648 cm−1 intensity Raman signal (RITC).VEGF-F-SERS-B dots revealed 
small dotted fluorescence signals (AF 610) and a 1324 cm−1 intensity Raman signal (FITC) (a.u. = arbitrary 
unit). (c) Characterization of HT29-effluc colon cancer cells. HT29-effluc cells showed high luciferase activity 
according to seeded cell number and a significant positive correlation with protein concentration (R2 = 0.987, 
P < 0.001). HT29-effluc cells demonstrated EGFR and VEGF expression by western blot analysis (the loading 
control used was β-actin; CPS = count per sec). (d) Confocal laser scanning microscopy (CLSM) after spraying 
10 µg of antibody-conjugated F-SERS dots onto cultured HT29-effluc cells. Multiple (EGFR-F-SERS-A and 
VEGF-F-SERS-B) or single (EGFR-F-SERS-A or VEGF-F-SERS-B) spraying of antibody-conjugated F-SERS 
dots were revealed by fluorescence, while the IgG-F-SERS-A/B dots (control) showed no fluorescence. Cell 
nuclei were labeled with DAPI.
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erosion symptoms (Fig. 4a) were found in 35% (7/20) of mice one week after injection and 86% (12/14) after 
two weeks (Supplementary Table 2). All mice showed moderate-to-high luciferase activity after one week (100%, 
20/20). The tumor-to-background ratio (TBR) two weeks after injection was significantly higher compared 
with the TBR one week after injection, according to the bioluminescence images (3354 ± 568 vs. 11021 ± 2400, 
P = 0.002*; Fig. 4b). The largest mean diameter of colon cancer tumors was 15 mm (range: 12–19 mm).
Validation of multiplex targeting ability of FRES. We attempted to validate the targeting ability of the 
two synthesized antibody-conjugated F-SERS dots. A total of 14 mice with tumors induced by injecting 1 × 107 
HT29-effluc cells after two weeks were studied: five in multiplex targeting, six in single targeting (three for EGFR 
and three for VEGF), and three as controls (IgG-F-SERS dots). FRES was able to simultaneously detect both 
fluorescence and multiple Raman spectra. The location of the targeted F-SERS dots was identified in real time 
using the fluorescence signals from the Alexa Fluor (AF) 610 dye. Raman bands at 1648 cm−1 and 1324 cm−1 were 
observed, which correspond to RITC for EGFR-F-SERS-A dots and FITC for VEGF-F-SERS-B dots, respectively 
(Fig. 4c). Definite signals were 80% (4/5) and probable signals were 20% (1/5) for mice in the multiplex target-
ing experiments. A single spray of antibody-conjugated F-SERS dots demonstrated definite fluorescence and 
corresponding Raman (RITC or FITC) signals in all cases (Fig. 4d and e). In contrast, in all cases of spraying 
IgG-F-SERS dots A/B as a control, no mice showed either fluorescence or Raman signals (Fig. 4f, Supplementary 
Fig. 4, and Supplementary Table 3). As a counter confirmation experiment, CLSM experiments were performed 
on the excised tumors which had shown definite binding of antibody-conjugated F-SERS dots to colon cancer 
cells but a lack of binding of IgG-F-SERS dots (Supplementary Fig. 5).
Orthotopic CRC xenograft modeling after injection of 1 × 107 HT29-effluc cells in a real-time 
endoscopic system. We next used the FRES imaging of the CRC xenograft model in a real-time endoscopic 
system. Among 20 studied mice with colorectal cancer, all showed moderate-to-high luciferase activity one week 
after injecting 1 × 107 HT29-effluc cells (100%, 20/20) with the largest mean diameter of colon cancer being 
13 mm (range: 11–17 mm); FRES imaging in the real-time endoscopic system is shown in Fig. 5a.
Validation of FRES in a real-time endoscopic system. We validated FRES imaging as a tool to detect 
tumors during real-time endoscopy. A total of 20 mice were investigated in a real-time endoscopic study of FRES 
(100 µg EGFR-F-SERS-A dots + 100 µg VEGF-F-SERS-B dots). In addition, 9 mice were studied as controls for 
a normal colon (100 µg EGFR-F-SERS-A dots + 100 µg VEGF-F-SERS-B dots). FRES showed specific targeting 
ability in a multiplex capacity in all the cases. Definite signals were observed in 75% (15/20) and probable signals 
in 25% (5/20) of mice with colorectal cancer (Fig. 5b). Immunohistochemistry (IHC) results demonstrated both 
Figure 3. In vitro FRES result according to dose of EGFR-F-SERS-A dots. HT29-effluc cells (104 cells/well) were 
seeded in an 8-well chambered coverglass with 300 μL of cell media per well. EGFR-F-SERS-A dots (0, 1, 5, 10, 
20, 40, 80, and 100 μg) were added to the wells, incubated at room temperature for 10 min, and washed three 
times with phosphate-buffered saline (PBS), after which FRES imaging was performed. Using FRES, definite 
EGFR-F-SERS-A dots bound to tumor cells were found by (a) fluorescence and (b) Raman signals from 5 μg 
(104/cm2). (c) When the Raman intensities at 1648 cm−1 were plotted, linear correlation was found until 40 μg, 
and saturation was found over 40 μg (104/cm2).
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EGFR and VEGF positivity in excised colorectal cancer, and hematoxylin and eosin (H&E) staining revealed 
tumor cell infiltration (Fig. 5c). Fluorescence and Raman signals were not observed in the normal colon controls 
(Fig. 5d, Supplementary Fig. 5, and Supplementary Table 4).
Orthotopic CRC xenograft modeling after injection of 5 × 106 HT29-effluc cells in a 
tumor-exposed system. The establishment of a xenograft model with small tumors using a lower dose 
of HT29-effuc cells was attempted. Among the 50 mice in the study group with tumors induced by 5 × 106 
HT29-effluc cells injection after one week, all showed mild-to-moderate luciferase activity (100%, 50/50), and 
the TBR showed significantly lower activity compared with the TBR of the group one week after injecting 1 × 107 
HT29-effluc cells (2055 ± 578 vs. 3354 ± 568, P = 0.044*; Fig. 6a). The largest mean diameter of colon cancer 
tumors was 7 m (range: 5–9 mm).
Identification of FRES sensitivity and the lower dose limit of antibody-conjugated F-SERS dots 
in small tumors. Twenty mice with colon cancer were treated with high doses (100 µg EGFR-F-SERS-A 
dots + 100 µg VEGF-F-SERS-B), another twenty with medium doses (50 µg EGFR-F-SERS-A dots + 50 µg 
VEGF-F-SERS-B), and the other ten with low doses (25 µg EGFR-F-SERS-A dots + 25 µg VEGF-F-SERS-B) of 
antibody-conjugated F-SERS dots for the determination of the sensitivity and the identification of the lower 
dose limit for FRES. In addition, eight mice as controls with normal colons were treated with high doses (100 µg 
Figure 4. Multiplex targeting validation of FRES. (a) Orthotopic colorectal cancer (CRC) xenograft modeling 
for FRES. Two weeks after injecting 1 × 107 HT29-effluc cells in mice, anal erosion was found (left) in most 
cases (86%, 12/14 mice), and the FRES imaging figure for the tumor-exposed system is shown on the right. (b) 
The bioluminescence image showed moderate-to-high activity in the colorectal area (left), and a significantly 
high tumor-to-background ratio (TBR, colorectal area/brain area) was identified at two weeks, compared with 
one week after injecting 1 × 107 HT29-effluc cells (right, 11021 ± 2400 vs. 3354 ± 568, P = 0.002*; n = 14). 
(c–f) FRES for multiplex targeting ability validation. After 10 min of incubation and PBS washing, tumors 
were investigated using a FRES probe. (c) After spraying 100 µg of EGFR-F-SERS-A dots and 100 µg of VEGF-
F-SERS-B dots, fluorescence signals were found by using AF 610, and two corresponding Raman signals were 
detected for RITC (-A) and FITC (-B) intensities. (d,e) After a single spraying dose of 100 µg each of EGFR-
F-SERS-A and VEGF-F-SERS-B dots, fluorescence signals and corresponding single Raman signals [RITC 
(-A) and FITC (-B)] were found. (f) In contrast, spraying of IgG-F-SERS-A/B dots demonstrated no distinct 
fluorescence and Raman signals.
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EGFR-F-SERS-A dots + 100 µg VEGF-F-SERS-B dots). FRES was able to detect CRC at high and medium doses 
of antibody-conjugated F-SERS dots in all of the cases. Definite signals were detected in 80% (16/20) and prob-
able signals in 20% (4/20) of animals for high dose antibody-conjugated F-SERS dots, and definite signals were 
detected in 75% (15/20) and probable signals in 25% (5/20) for medium dose antibody-conjugated F-SERS dots 
(Fig. 6b). For the low dose antibody-conjugated F-SERS dots group, 50% (5/10) showed definite signals and 30% 
(3/10) were probable signals. No signal was found for low dose antibody-conjugated F-SERS dots in 20% (2/10) 
(Fig. 6c). Fluorescence and Raman signals were not observed in all of the control group of normal colon cases 
(Fig. 6d, Supplementary Fig. 7, and Supplementary Table 5). CLSM images of tumor sections showed definite 
binding when high, medium, and low doses of antibody-conjugated F-SERS dots were used, while binding of 
antibody-conjugated F-SERS dots on normal colons was not detected (Supplementary Fig. 8).
Discussion
We have shown that FRES is a useful endoscopic tool in an orthotopic CRC xenograft model using 
antibody-conjugated F-SERS dots. FRES has advantages in that it allows the fast simultaneous detection of fluo-
rescence and Raman signals. Fluorescence signals were useful for fast tracking of lesions, and Raman signals were 
helpful for multiplex target identification (both tumor cells and tumor microenvironment) and quantification. 
Most of all, we identified that FRES could be useful in an in vivo real-time endoscopic system as a practical diag-
nostic tool. In addition, we confirmed the multiplex targeting ability of FRES in subcentimeter-sized colorectal 
cancers by lowering the spraying dose of antibody-conjugated F-SERS dots according to tumor size, thereby 
verifying the sensitivity of FRES.
The main advantage of FRES is that it can be easily applied to a conventional endoscopic system since it has 
an optical fiber bundle probe which can be inserted into the accessory channel of a conventional endoscope20. 
Fluorescence-based techniques can improve the detection ability of a routine colonoscopy with low cost and 
the use of a probe that lacks toxicity, but they also have limitations in that usually, only one target signal can be 
detected due to its broad bandwidth and autofluorescence from tissue leads to false-positive results21–23. In con-
trast, SERS-based techniques have advantages such as high sensitivity and multiplex targeting abilities, but show 
limitations such as a small field of view and limited study data23–26. In contrast, FRES can take advantage of com-
bining a large field of view (fluorescence signal) and a multiplex ability (SERS signal) for dual-modality imaging, 
resulting in the rapid and accurate characterization of lesions.
Figure 5. Evaluation of FRES in a real-time endoscopic system. (a) Orthotopic CRC xenograft modeling. 
One week after injecting 1 × 107 HT29-effluc cells, bioluminescence imaging (left) showed moderate-to-high 
activity in the colorectal area of mice (lateral view; n = 20). The FRES imaging method used in a real-time 
endoscopic system is shown (right). (b) Mice with CRC (two weeks after injecting 1 × 107 of HT29-effluc cells) 
were investigated in a real-time endoscopic study of FRES. After spraying 100 µg each of EGFR-F-SERS-A and 
VEGF-F-SERS-B dots, fluorescence signals were found as well as two corresponding Raman signals [RITC 
(-A) and FITC (-B)]. (c) Tumors were excised, fixed, and sectioned. EGFR and VEGF positivity was identified 
by immunohistochemistry (IHC), and tumor cell infiltration was observed by hematoxylin and eosin (H&E) 
staining. (d) After spraying 100 µg each of EGFR-F-SERS-A and VEGF-F-SERS-B dots on normal colons 
(control), no fluorescence or Raman signals were detected.
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The molecular characterization of CRC is very important for the selection of the most appropriate treatment 
option as well as for patients’ prognosis and quality of life. For CRC, EGFR (anti-EGFR monoclonal antibody: 
cetuximab) and VEGF (anti-VEGF monoclonal antibody: bevacizumab) targeting is the standard therapy that 
prolongs survival in patients with metastatic disease19, and previous studies have shown that molecular imaging 
of EGFR27 and VEGF28, 29 can be performed in vivo, so we decided that the FRES imaging targets should be EGFR 
and VEGF. As EGFR targets the cellular membrane30, and VEGF targets the extracellular matrix31, our study 
showed simultaneous tumor cell and tumor microenvironment imaging. In addition, our previous pilot study for 
targeting EGFR and HER2 using the HT29-effluc cells xenograft model showed duplex cellular targeting ability 
(Supplementary Fig. 9).
IHC has been routinely used for molecular diagnosis but can yield false positive/negative results due to tech-
nical and interpretative pitfalls32. Fixation and tissue processing artifacts, as well as antigen retrieval errors during 
IHC procedures, can hamper the exact evaluation of a tumor’s characteristics. Additionally, 2–3 days delay in 
evaluation after a colonoscopy may cause a loss of optimal treatment time33, 34. With FRES, we can achieve mul-
tiple molecular characteristics while performing real-time colonoscopies with high accuracy, resulting in rapid 
and effective diagnoses.
For the successful clinical application of FRES, major issues such as stability, signal sensitivity, specificity, 
and toxicity of F-SERS dots were properly addressed35. First, the optical stability of the F-SERS dots was tested. 
Fluorescence and Raman signals did not decline or change during surface modification and antibody conjuga-
tion, and emitted the same fluorescence and Raman signal intensity more than 1 year after synthesis. In regard 
to the issue of sensitivity, we performed a FRES study on small tumors (less than 1 cm) that showed a similar 
multiplex targeting ability to the one for large tumors (greater than 1 cm). For the specificity issue, we performed 
a blocking study and demonstrated that FRES signals were selectively blocked by cold antibodies (Supplementary 
Fig. 10). In regard to toxicity, we reduced systemic toxicity by using a topical administration method via directly 
spraying antibody-conjugated F-SERS dots onto the tumor, thereby bypassing the major disadvantages of intra-
venous injection: systemic toxicity caused by accumulation in major organs (lung, liver and spleen)36–39 and a 
decreased tumor-targeting ability due to the large size of antibody-conjugated F-SERS dots40. In addition, we 
introduced a silica shell (nontoxic coating) for the F-SERS dots, which is well known to reduce the toxicity of 
nanoparticles41–43. Furthermore, we observed that antibody-conjugated F-SERS dots did not accumulate in 
the normal colon after washing, thus further reducing any toxicity towards normal organs. Last, a half dose of 
antibody-conjugated F-SERS dots used for small tumors showed similar FRES results to a high dose; spraying 
50 + 50 µg of antibody-conjugated F-SERS dots (5 nmol) onto a small tumor was found to be acceptable.
One important point of our study is the quantification of Raman intensity. As the Raman signal showed high 
signal intensity, the intensity could be quantified by measuring the highest peak of the Raman bands. The in 
vitro study demonstrated that Raman intensity increases according to EGFR-F-SERS-A dot doses, or seeded cell 
Figure 6. Evaluation of sensitivity and lower dose limit of FRES. (a) Orthotopic CRC xenograft modeling for 
small tumors. After one week of injecting 5 × 106 HT29-effluc cells in mice, bioluminescence imaging showed 
mild-to-moderate activity in the colorectal area (left). A significantly lower TBR was found compared with 
that of mice one week after injecting 1 × 107 HT29-effluc cells (2,055 ± 578 vs. 3,354 ± 568, P = 0.044*) (right). 
(b) After spraying 50 µg of EGFR-F-SERS-A and VEGF-F-SERS-B dots onto small tumors in a CRC xenograft 
model, fluorescence signals were observed, and two corresponding Raman signals [RITC (-A) and FITC (-B)] 
were found. (c) On the other hand, after spraying 25 µg each of EGFR-F-SERS-A and VEGF-F-SERS-B dots, a 
faint fluorescence signal and no Raman signal was found in some cases (20%, 2/10). (d) In the normal colon 
(control), no fluorescence or Raman signals were found corresponding EGFR-F-SERS-A and VEGF-F-SERS-B 
dots.
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density. Moreover, we were able to evaluate different molecular expression within tumors using FRES with quan-
tification of Raman intensity ex vivo (Supplementary Fig. 11)44.
In this study, we achieved duplex targeting using both types of F-SERS dots although we did not fully exploit 
the SERS- capability in multiplex testing. Furthermore, as we targeted the EGFR tumor marker on the surface 
of tumor cells and tumor-secreted VEGF in the tumor microenvironment, this study could now be extended 
to include the surface epitopes of immune or stromal cells including fibroblasts and other secreted peptides or 
cytokines prevalent in the tumor microenvironment. Though surface modification of F-SERS dots with three 
commercialized monoclonal antibodies (cetuximab, bevacizumab, and herceptin) was successful, surface labeling 
with other collections of antibodies should be performed and validated individually, and for optimal multiplex-
ing, the selection of the SERS dots as well as their preparation and validation should be performed once again.
In conclusion, we demonstrated that FRES can be utilized in multiplex molecular diagnosis which can be 
easily applied to routine endoscopy. By using this technique, the multiple molecular characteristics of a tumor 
(tumor cell and tumor microenvironment) can be acquired simultaneously while performing a colonoscopy, and 
this could be effective in the early and most appropriate selection of treatment options. In addition, FRES can be 
applied to small tumors by lowering the dose of topically sprayed F-SERS dots, which can minimize the toxicity 
problem when applied clinically. We expect that FRES will eventually become an appropriate endoscopic tech-
nique for the rapid and specific diagnosis of CRC.
Methods
Fluorescence-Raman endoscopic system (FRES). The optical setup for FRES is described in our pre-
vious study16. In brief, in order to simultaneously detect both fluorescence and Raman signals, FRES consists of 
three units: (1) a dual-axis laser-scanning unit, (2) a separation unit, and (3) a signal-detecting unit. The dual-axis 
laser-scanning unit (Raman prototype of Cell-VizioTM; Mauna Kea Technologies, Paris, France) has two orthog-
onally oscillating mirrors that allow the sequential injection of a laser line into each one of a bundle of optical 
fibers for light incidence. To introduce the laser line to the sample and collect optical signals from the sample, a 
fiber-optic probe having a 2.6 mm external diameter, a 60 μm working distance, and a 240 μm field-of-view was 
utilized. As an excitation source, a continuous wave diode-pumped solid-state 532 nm laser (Cobolt SambaTM; 
Cobolt AB, Solna, Sweden) was used, coupled with a single mode fiber. The separation unit uses two optical 
filters: a long-pass dichroic filter (FF593-Di03-25D; Semrock Inc., Rochester, NY, USA) for passing the fluores-
cence signal from the collected signal, and an edge filter (LP03-532RS-25; Semrock Inc., Rochester, NY, USA) for 
the rejection of Rayleigh-lights and the passing of Raman-scattering lights. To simultaneously provide real-time 
fluorescence images and Raman spectra, the signal detecting unit consists of two independent detectors: an ava-
lanche photodiode for fluorescence signal detection and a spectrometer (SR 303i-A; Andor Technology, Belfast, 
UK) with a thermo-electrically cooled CCD detector (DV401A-BV; Andor Technology, Belfast, UK) for Raman 
signal detection. The collected fluorescence signals were processed into real-time fluorescence images by imaging 
software (ImageCell; Mauna Kea Technologies, Paris, France) (Supplementary Fig. 12).
Preparation of fluorescence & surface-enhanced Raman scattering probes (F-SERS 
dots). F-SERS dots were synthesized according to the previously reported method16. Briefly, 200 nm-sized 
silica nanoparticles (NPs) were synthesized according to the Stöber method45. Tetraethyl orthosilicate (TEOS; 
1.6 mL) in 40 mL of absolute ethanol was reacted with 3 mL ammonium hydroxide (NH4OH) for 20 h at 
room temperature. After thiol-functionalization on the surface of silica NPs (10 mg) by reacting with 100 μL 
3-mercaptopropyltrimethoxysilane (MPTS) and 20 μL NH4OH (27%) for 2 h at room temperature, silver NPs 
were directly introduced onto the surface of the silica NPs by reducing 3 mM silver nitrate (AgNO3) in eth-
ylene glycol with 10 mM octylamine for 1 h. To encode with Raman-labeling compounds, silver-embedded 
silica (Ag-Si) NPs were treated with 1 mM RITC or 1 mM FITC, respectively. The Raman-labeled Ag-Si NPs 
were then encapsulated with a silica shell using TEOS and NH4OH. Further encapsulation with fluorescent 
dye (AF 610)-conjugated silica shells was performed in a TEOS (10 μL), NH4OH (0.5 mL, 27%), and AF610-
3-aminopropyltriethoxysilane (APTES; 55 μL) conjugated solution previously prepared by reacting 5 μL AF610 
(8 mM in dimethyl sulfoxide (DMSO)) with 50 μL APTES (19.2 mM in ethanol) for 15 h. The final synthesized 
nanoprobes [F-SERS-A dots (using RITC) and -B dots (using FITC)] were washed with ethanol several times for 
purification purposes and then redispersed in ethanol.
Establishment of colorectal cancer cell lines and their evaluation. The human colorectal adeno-
carcinoma cell line (HT29), which is known to express EGFR and VEGF46, was acquired from the Korean Cell 
Line Bank (KCLB, Seoul, Korea). HT29 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; 
Invitrogen, Grand Island, NY, USA) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 
100 g/mL streptomycin at 37 °C in a humidified atmosphere containing 5% CO2. A retroviral vector containing 
codon-optimized firefly luciferase complementary DNA (effluc), and Thy1.1 (CD90.1), which is linked with an 
internal ribosomal entry site (IRES), was constructed for use in enhanced bioluminescence cell imaging47, 48. 
HT29 cells were transfected with a recombinant retroviral vector encoding a luciferase gene (HT29-effluc). To 
determine whether the luciferase gene was expressed in the established HT29-effluc cells, the latter were seeded 
into a 24-well plate and an in vitro luciferase assay was performed according to the seeded cell number and pro-
tein concentration using a luminometer (TR717p; Applied Biosystems, Grand Island, NY, USA). Protein concen-
trations were measured using BCA protein assay kits (Thermo Scientific, Rockford, IL, USA).
Modeling of orthotopic colorectal cancer (CRC) xenografts. All animal protocols were approved by 
the Institutional Animal Care and Use Committee of the Seoul National University College of Medicine, and all 
experiments were performed in accordance with relevant guidelines and regulations. Six-week-old male BALB/c 
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nude mice were obtained from Orient Bio, Inc. (Seoul, Korea) and housed in a specific, pathogen-free environ-
ment. CRC xenograft mice were divided into three groups:
 (1) Injection of 1 × 107 of HT29-effluc cells for FRES imaging in a tumor-exposed system (n = 20; validation of 
the multiplex targeting ability of FRES).
 (2) Injection of 1 × 107 of HT29-effluc cells for FRES imaging in an endoscopic system (n = 20; validation of 
FRES as a real-time endoscopic system).
 (3) Injection of 5 × 106 of HT29-effluc cells for FRES imaging in a tumor-exposed system (n = 50; validation of 
FRES sensitivity and the lower dose limit of antibody-conjugated F-SERS dots for small tumors).
Before each injection of tumor cells, mice were anesthetized with an intramuscular injection of 200 µL of 0.5% 
zoletil 50 (tiletamine-zolazepam; Virbac S.A., Carros, France) and 0.2% xylazine (Rompun; Bayer, Leverkusen, 
Germany) solution (1:1). Using a 30-gauge needle, a 0.1 mL volume of complex (containing tumor cells at a 1:1 
ratio in medium/matrigel) was injected into the posterior colorectal wall via the anus49, 50. Tumor growth was 
investigated over two weeks for the injection of 1 × 107of HT29-effluc cells groups, and over one week for the 
injection of 5 × 106 of HT29-effluc cells group.
In vitro and in vivo validation of FRES measurements. As a tumor targeting agent, 
antibody-conjugated F-SERS dots were measured in a conical tube. Fluorescence and Raman signals were iden-
tified simultaneously to investigate the binding of antibody-conjugated F-SERS dots with colon cancer cells. 
First, we identified the sensitivity and correlation of Raman intensity according to dose of antibody-conjugated 
F-SERS dots using FRES. HT29-effluc cells (104 cells/well) were seeded in an 8-well chambered coverglass 
(Lab-Tek; Thermo Scientific, Rochester, NY, USA) with 300 μL of cell media per well. After 24 h incubation at 
37 °C, cells were fixed with 4% paraformaldehyde (Wako, Osaka, Japan) for 20 min, and washed three times with 
phosphate-buffered saline (PBS). EGFR-F-SERS-A dots (0, 1, 5, 10, 20, 40, 80 and 100 μg; 5 mg/mL concentration 
in PBS solution containing 1% bovine serum albumin (BSA) were added to a well, incubated at room temper-
ature for 10 min, washed three times with PBS, and FRES imaging was performed for 3 min. In addition, we 
confirmed FRES imaging differences according to seeded cell density (0, 103, 104, and 105 cells/well) with 10 μg of 
EGFR-F-SERS-A dots in the same manner.
For the in vivo studies, mice with CRC were initially anesthetized with an intramuscular injection of 200 µL 
of 0.5% zoletil 50 (tiletamine-zolazepam; Virbac S.A., Carros, France) and 0.2% xylazine (Rompun; Bayer, 
Leverkusen, Germany) solution (1:1). In the tumor-exposed system, after making an incision of the skin and 
anterior wall of the colorectal area, tumors were exposed and tumor sizes were measured using a digital caliper.
To validate the multiple targeting ability of FRES, 100 μg each of antibody-conjugated F-SERS dots 
(EGFR-F-SERS-A and VEGF-F-SERS-B: 20 μL volume with 5 mg/mL concentration in PBS solution containing 1% 
BSA) were sprayed onto the surface of a 1 × 107 HT29-effluc cell-injected tumor using a micropipette (AxyPetTM 
single-channel pipettor via the anus. After 10 min of incubation, the antibody-conjugated F-SERS dots were 
washed five times with 300 μL of PBS. Fluorescence and Raman spectra of tumors were simultaneously measured 
in the tumor area using FRES for 3 min. A single treatment with 100 μg each of antibody-conjugated F-SERS dots 
(EGFR-F-SERS-A or VEGF-F-SERS-B) or IgG-F-SERS-A/B dots (control) was also performed in the same manner.
To validate FRES for a real-time endoscopic system, 100 μg of antibody-conjugated F-SERS dots were 
sprayed onto the lumen of the colon through the anus. After 10 min of incubation, antibody-conjugated F-SERS 
dots-treated areas were washed five times with 300 μL of PBS. The multiplexing capability of FRES was investi-
gated for 3 min by inserting a probe into the colon through the anus of tumor-implanted and normal mice.
To validate the lower dose limit of the antibody-conjugated F-SERS dots using FRES in a small tumor, different 
amounts of the former were sprayed onto the surface of a 5 × 106 HT29-effluc cell-injected tumor and evaluated 
by FRES as described above. The groups under the study were as follows:
 (1) High dose: 100 μg each of EGFR-F-SERS-A and VEGF-F-SERS-B dots on a tumor.
 (2) Medium dose: 50 μg each of EGFR-F-SERS-A and VEGF-F-SERS-B dots on a tumor.
 (3) Low dose: 25 μg each of EGFR-F-SERS-A and VEGF-F-SERS-B dots on a tumor.
 (4) Control: 100 μg each of EGFR-F-SERS-A and VEGF-F-SERS-B dots on a normal colon.
The multiplex targeting ability of FRES was graded into three levels:
 (1) A “definite signal” occurred when the two known Raman signals were clearly observed after a fluorescence 
signal had been found [over 30 counts per second (cps) for both Raman signals], considering more than 
three times of background level (10 cps).
 (2) A “no signal” occurred when neither Raman nor fluorescence signals were observed (between 0 to 20 cps 
of either or both Raman signals).
 (3) A “probable signal” occurred when either Raman signal was between a definite and a no signal state, but 
not necessarily both after a fluorescence signal was found.
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